Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)

References

• Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN. Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis. 2019;6:S23–S33. doi:10.1093/ofid/ofy347
   Web of Science ®Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N Engl J Med. 2020;382:1309–1319. doi:10.1056/NEJMoa1914433
   PubMed Web of Science ®Google Scholar
• Magill SS, O’Leary E, Ray SM, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2021;72:1784–1792. doi:10.1093/cid/ciaa373
   PubMed Web of Science ®Google Scholar
• Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN. Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997–2016. Open Forum Infect Dis. 2019;6:S63–S68. doi:10.1093/ofid/ofy343
   Web of Science ®Google Scholar
• Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol. 2020;41:1–18. doi:10.1017/ice.2019.296
   PubMed Web of Science ®Google Scholar
• Ashley EA, Lubell Y, White NJ, Turner P. Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub-Saharan Africa and Asian low and middle income countries. Trop Med Int Health. 2011;16:1167–1179. doi:10.1111/j.1365-3156.2011.02822.x
   PubMed Web of Science ®Google Scholar
• Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, Sentry ASG. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–1999). Diagn Microbiol Infect Dis. 2002;42:193–198. doi:10.1016/S0732-8893(01)00353-4
   PubMed Web of Science ®Google Scholar
• Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among Gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the tigecycline evaluation and surveillance trial. Clin Ther. 2012;34:124–137. doi:10.1016/j.clinthera.2011.11.023
   PubMed Web of Science ®Google Scholar
• Chen YH, Hsueh PR, Badal RE, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62:280–291. doi:10.1016/j.jinf.2011.02.009
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect. 2010;60:440–451. doi:10.1016/j.jinf.2010.03.024
   PubMed Web of Science ®Google Scholar
• Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diagn Microbiol Infect Dis. 2005;52:323–329. doi:10.1016/j.diagmicrobio.2005.04.004
   PubMed Web of Science ®Google Scholar
• Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37:291–295. doi:10.1016/j.ijantimicag.2011.01.009
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): report from an antimicrobial surveillance program (2013–2015). Int J Antimicrob Agents. 2018;51:181–189. doi:10.1016/j.ijantimicag.2017.09.016
   Web of Science ®Google Scholar
• Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis. 2013;76:61–68. doi:10.1016/j.diagmicrobio.2013.01.005
   PubMed Web of Science ®Google Scholar
• Sheng WH, Badal RE, Hsueh PR, Program S. Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57:2981–2988. doi:10.1128/AAC.00971-12
   PubMed Web of Science ®Google Scholar
• Turnidge J, Bell J, Biedenbach DJ, Jones RN. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY antimicrobial surveillance program, 1998–1999. Int J Antimicrob Agents. 2002;20:10–17. doi:10.1016/S0924-8579(02)00050-X
   PubMed Web of Science ®Google Scholar
• Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis. 2011;53(Suppl 2):S33–S55. doi:10.1093/cid/cir475
   PubMed Web of Science ®Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42:S82–S89. doi:10.1086/499406
   PubMed Web of Science ®Google Scholar
• Zhang D, Micek ST, Kollef MH. Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med. 2015;43:2133–2140. doi:10.1097/CCM.0000000000001140
   PubMed Web of Science ®Google Scholar
• Lizza BD, Betthauser KD, Ritchie DJ, Micek ST, Kollef MH. New perspectives on antimicrobial agents: ceftolozane-tazobactam. Antimicrob Agents Chemother. 2021;65:e0231820. doi:10.1128/AAC.02318-20
   PubMed Web of Science ®Google Scholar
• Munita JM, Aitken SL, Miller WR, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017;65:158–161. doi:10.1093/cid/cix014
   PubMed Web of Science ®Google Scholar
• Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrob Resist Infect Control. 2021;10:68. doi:10.1186/s13756-021-00933-8
   Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–6310. doi:10.1128/AAC.01802-13
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533–539. doi:10.1016/j.ijantimicag.2014.01.032
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–2012). J Antimicrob Chemother. 2014;69:2713–2722. doi:10.1093/jac/dku184
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69:266–277. doi:10.1016/j.jinf.2014.04.004
   PubMed Web of Science ®Google Scholar
• Fuhrmeister AS, Jones RN. The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program. Open Forum Infect Dis. 2019;6:S1–S4. doi:10.1093/ofid/ofy346
   Web of Science ®Google Scholar
• CLSI. M07ED11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• CLSI. M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing; 2021.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of America guidance on the treatment of Extended-Spectrum Beta-Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72:e169–e183. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71:e523–e529. doi:10.1093/cid/ciaa121
   PubMed Web of Science ®Google Scholar